ID   SV-BR-1-GM
AC   CVCL_4U13
SY   SVBR-1-GM
DR   ATCC; PTA-7813
DR   Wikidata; Q54970930
RX   Patent=US7674456;
RX   PubMed=16958969;
RX   PubMed=29867922;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7813.
CC   Characteristics: ER/PR-negative and ERBB2-positive.
CC   Transfected with: HGNC; 2434; CSF2.
CC   Derived from site: Metastatic; Chest wall; UBERON=UBERON_0016435.
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4U12 ! SV-BR-1
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 29-06-23; Version: 6
//
RX   Patent=US7674456;
RA   Wiseman C.L., Kharazi A.;
RT   "Breast cancer cell lines and uses thereof.";
RL   Patent number US7674456, 09-Mar-2010.
//
RX   PubMed=16958969; DOI=10.1111/j.1075-122X.2006.00319.x;
RA   Wiseman C.L., Kharazi A.;
RT   "Objective clinical regression of metastatic breast cancer in
RT   disparate sites after use of whole-cell vaccine genetically modified
RT   to release sargramostim.";
RL   Breast J. 12:475-480(2006).
//
RX   PubMed=29867922; DOI=10.3389/fimmu.2018.00776;
RA   Lacher M.D., Bauer G., Fury B., Graeve S., Fledderman E.L.,
RA   Petrie T.D., Coleal-Bergum D.P., Hackett T., Perotti N.H., Kong Y.Y.,
RA   Kwok W.W., Wagner J.P., Wiseman C.L., Williams W.V.;
RT   "SV-BR-1-GM, a clinically effective GM-CSF-secreting breast cancer
RT   cell line, expresses an immune signature and directly activates CD4(+)
RT   T lymphocytes.";
RL   Front. Immunol. 9:776.1-776.23(2018).
//